Prostate Cancer News
Erleada plus ADT achieved statistical significance in meeting both primary end points of OS and rPFS in the phase 3 TITAN study.
In a study, Japanese men who ate mushrooms each week had lower risk for prostate cancer.
In a phase 2 trial of men with metastatic castration-resistant prostate cancer, cabazitaxel plus carboplatin significantly prolonged progression-free survival compared with cabazitaxel alone.
In a study of radical prostatectomy patients with Gleason score 7 prostate cancer, the risk for biochemical recurrence more than doubled in the presence of tertiary pattern 5 disease.
Researchers sought to demonstrate how recalibration of risk stratification tools can improve accuracy and clinical decision making.
Simply living in a rural area made it less likely an individual with prostate cancer to receive treatment, with the exception of radiation.
A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
In a study of men with Gleason 8 to 10 prostate cancer and low PSA, radical prostatectomy was associated with better survival odds than external beam radiation therapy with or without brachytherapy.
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.
Study shows cT2 subclassifications as determined by digital rectal examination, independent predicts mortality risk in men with prostate cancer.
Androgen deprivation therapy for prostate cancer is associated with a significant 20% increased risk of dementia and 14% increased risk of Alzheimer’s disease, a study found.
Urine-derived extracellular vesicle RNA provides diagnostic, prognostic information in prostate cancer.
Men on active surveillance for prostate cancer progress to treatment sooner if they undergo multiparametric MRI to identify clinically significant tumors.
In a study, patients who underwent salvage cryotherapy for radiorecurrent prostate cancer had cancer-specific and metastasis-free survival rates of 81% and 78%, respectively, at 12 years.